4D pharma plc

4D pharma says phase II IBS results published in scientific journal

4D Pharma outlines phase II plans for promising cancer drug candidate

4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate

4D Pharma has a busy year ahead after a successful 12 months of clinical research

4D Pharma PLC soars after meeting endpoint early

4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

4D pharma sees early success as phase I/II cancer trial hits its efficacy target early

4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates

4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy

4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma

4D pharma hails 'highly encouraging' data from its early-stage asthma trial

4D pharma hires new CFO

4D pharma says asthma live biotherapeutic shows ‘promising' early signs of clinical activity

4D pharma to present new insights from IBS study

4D Pharma interim results mark major milestones

4D Pharma interims marks major milestones

4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology (ESMO) Congress 2021

4D pharma to display two posters showcasing positive data for cancer asset at oncology conference

4D pharma to display two posters showcasing positive data for cancer treatment at oncology conference